BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company ...

"Driven by EHR adoption, cost-efficiency goals, and IoT integration, the healthcare predictive analytics market is reshaping care delivery with data-driven insights that enhance outcomes, optimize ...

PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response data ...

Predictive Oncology aims to enhance drug discovery using its biobank and AI, following industry trends exemplified by Regeneron's 23andMe acquisition. Predictive Oncology Inc. is leveraging its ...

BostonGene has entered a new collaboration with AstraZeneca to apply its foundation AI model to oncology drug development, aiming to improve early trial decision-making around safety, efficacy, and ...

Stanford Medicine has developed a vision-language artificial intelligence (AI) model that can predict cancer outcomes, such as forecasting melanoma relapses and patient responses to immunotherapy.

The global market for healthcare predictive analytics is expected to grow from $16.7 billion in 2025 and is projected to reach $50.4 billion by the end of 2030, at a compound annu ...

Update (Oct. 1, 00:30 UTC): This article has been updated to include comments from DNA Fund co-founder Chris Miglino. Predictive Oncology (POAI), a biotechnology company specializing in AI-driven ...

Predictive Oncology, Inc. (NASDAQ:POAI) shares are trading higher on Tuesday after the company announced it developed predictive models to target various cancer types. The Details: The models were ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...